Evaxion Biotech A/S

Equities

EVAX

US29970R2040

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-05-21 pm EDT 5-day change 1st Jan Change
3.57 USD -4.03% Intraday chart for Evaxion Biotech A/S -4.03% -47.94%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% MT
Evaxion Biotech A/S Elects Lars Staal Wegner as A New Board Member CI
Evaxion Announces Phase 2 Clinical Trial Update CI
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading MT
Certain Warrants of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
Certain American Depositary Shares of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
Certain Ordinary Shares of Evaxion Biotech A/S are subject to a Lock-Up Agreement Ending on 7-APR-2024. CI
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
ADRs End Lower; Meta Data Slides 22% DJ
Sector Update: Health Care Stocks Slide Late Afternoon MT
Sector Update: Health Care Stocks Slipping in Afternoon Trading MT
Evaxion's EVX-B1 Vaccine Shows Promising Protection Against Staph Infections in Preclinical Studies; Shares Jump MT
Ladenburg Thalmann Upgrades Evaxion Biotech to Buy From Neutral, Price Target is $8 MT
Transcript : Evaxion Biotech A/S, 2023 Earnings Call, Apr 02, 2024
Chart Evaxion Biotech A/S
More charts
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.57 USD
Average target price
11.75 USD
Spread / Average Target
+229.13%
Consensus
  1. Stock Market
  2. Equities
  3. EVAX Stock
  4. News Evaxion Biotech A/S
  5. European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW